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Abstract
Background Hypertension is often inadequately con-
trolled in older people.
Objective This prespecified subgroup analysis assessed
the efficacy and safety of an olmesartan medoxomil (OM)
40 mg/amlodipine besylate (AML) 10 mg/hydrochlorothi-
azide (HCTZ) 25 mg triple-combination treatment com-
pared with the 3 components as dual-combination
treatments in participants with hypertension who were\65
and C65 years of age. Within the C65 years of age sub-
group, efficacy and safety were also summarized for par-
ticipants C75 years of age.
Study design 12-week, multicenter, double-blind, ran-
domized, parallel-group study.
Setting 317 ambulatory care sites in the US and Puerto
Rico.
Participants Individuals C18 years of age with mean
seated blood pressure (SeBP) C140/100 or C160/
90 mmHg off antihypertensive medication on 2 consecu-
tive clinic visits with no recent history of significant
cerebrovascular disease, coronary artery disease, heart
failure (New York Heart Association class III or IV),
severe renal insufficiency, or uncontrolled diabetes (HbA1c
[9 %).
Intervention Participants were randomized, stratified by
age, diabetes status, and race to one of four treatment
assignments: OM 40/AML 10/HCTZ 25 mg, OM 40/AML
10 mg, OM 40/HCTZ 25 mg, or AML 10/HCTZ 25 mg.
Main Outcome Measure Least squares (LS) mean change
from baseline in seated diastolic blood pressure (SeDBP) at
week 12 (last observation carried forward) in each age
subgroup (prespecified analysis).
Results Of the 2492 randomized participants in the study
(total cohort), 2021 (81.1 %) were \65 and 471 (18.9 %)
were C65 years of age, including 79 (3.2 %) who were
C75 years of age. OM 40/AML 10/HCTZ 25 mg triple-
combination treatment resulted in a significantly greater
reduction in LS mean SeDBP at week 12 than dual-com-
bination component treatments in participants in both
cohorts:\65 years (21.0 vs. 14.2–17.2 mmHg; p \0.0001)
and C65 years (23.7 vs. 17.3–20.0 mmHg; p B 0.002).
Similarly, triple-combination treatment resulted in a greater
reduction in LS mean seated systolic blood pressure (SeSBP)
at week 12 than dual-combination component treatments:
\65 years (38.2 vs. 28.3–31.4 mmHg; p \ 0.0001) and
C65 years (39.2 vs. 29.3–31.1 mmHg; p \ 0.0001). Triple-
combination treatment was more effective than dual-com-
bination treatments in enabling participants to reach SeBP
goal (\140/90 mmHg [\130/80 mmHg in participants with
diabetes, chronic kidney disease, or chronic cardiovascular
disease]) in both age subgroups (\65 years: 65 vs. 34–50 %,
respectively, p \ 0.0001 and C65 years: 63 vs. 32–39 %;
p B 0.0004). All 4 treatments were safe and well tolerated
with low discontinuation rates in both age subgroups. There
were no clinically relevant differences in the incidence of
treatment-emergent adverse events between participants
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\65 and C65 years of age receiving triple-combination
treatment.
Conclusion Triple-combination treatment with OM
40/AML 10/HCTZ 25 mg was well tolerated and more
effective in lowering BP than the component dual-combi-
nation treatments in elderly and non-elderly subgroups.
1 Introduction
The prevalence of hypertension rises with age [1–4]. In the
US, hypertension occurs in 70.8 % of women and 63.9 %
of men 65–74 years of age and 80.1 % of women and
72.1 % of men C75 years of age, largely due to increased
systolic blood pressure (SBP) [1]. Individuals over
60 years of age are also the most rapidly growing segment
of the US population. By 2025, the worldwide prevalence
of hypertension will reach 50.3 % in women and 46.0 % in
men 60–69 years of age and 66.8 % in women and 57.1 %
in men C70 years of age [5].
Adequately treating hypertension is important since
cardiovascular disease risk is doubled with each 7 years
of advancing age, 20-mmHg increment in SBP, or
10-mmHg increment in diastolic BP (DBP) [6]. National
Health and Nutrition Examination Survey (NHANES)
data indicate that only 53 % of individuals C60 years of
age have adequate BP control [1]. In order to achieve
adequate BP reduction, many elderly individuals require
more than one drug [7]. If multiple-pill therapies
adversely affect therapeutic adherence in this population
[8, 9], many elderly patients with hypertension may
benefit from single-pill, multiple-combination therapy
[5, 10, 11].
In the Triple Therapy with Olmesartan Medoxomil,
Amlodipine, and Hydrochlorothiazide in Hypertensive
Patients Study (TRINITY; ClinicalTrials.gov Identifier:
NCT00649389), the triple-combination treatment of
olmesartan medoxomil (OM) 40 mg, amlodipine besylate
(AML) 10 mg, and hydrochlorothiazide (HCTZ) 25 mg
reduced both seated DBP (SeDBP) and seated SBP (SeS-
BP) to a greater degree than the 3 dual-combination
treatments, enabling a greater proportion of study partici-
pants to reach BP goal (\140/90 mmHg [\130/80 mmHg
in participants with diabetes, chronic kidney disease, or
chronic cardiovascular disease]) [12]. The objective of the
current prespecified TRINITY subgroup analysis was to
evaluate the efficacy and safety of the OM 40/AML
10/HCTZ 25 mg triple-combination treatment compared
with the 3 component dual-combination treatments in
participants with hypertension who were \65 and
C65 years of age. Within the C65 years of age subgroup,
efficacy and safety were also summarized for participants
C75 years of age.
2 Methods
2.1 Study Population
The detailed TRINITY study design and results of the
12-week randomized phase for the total population have
been previously reported [12]. Briefly, the TRINITY study
was a multicenter, double-blind, randomized, parallel-
group trial conducted at 317 clinical sites in the US and
Puerto Rico. Individuals eligible for randomization were
C18 years of age with mean seated BP (SeBP) C140/100
or C160/90 mmHg on 2 consecutive visits off antihyper-
tensive medication. Persons with a recent history
(B6 months) or presence of significant cardiovascular or
cerebrovascular disease, coronary artery disease, New
York Heart Association class III or IV congestive heart
failure, severe renal insufficiency (defined as creatinine
clearance \30 mL/min), or uncontrolled diabetes (defined
as hemoglobin A1c[9 %) were excluded. Individuals with
type 1 or type 2 diabetes whose diabetes was controlled for
C30 days by a stable regimen of diet, insulin, or oral
hypoglycemic agents and persons with chronic kidney
disease (creatinine clearance C30 and B60 mL/min) were
eligible to participate. The study was conducted in accor-
dance with the institutional review board committee reg-
ulations and the Declaration of Helsinki, and written
informed consent was obtained from each individual before
participation in any study procedures.
2.2 Study Design and Procedures
The study included a 3-week washout period (for partici-
pants receiving antihypertensive treatment at screening)
followed by a 12-week double-blind treatment period. On
day 1, eligible study participants were randomized using an
interactive voice response system to a treatment sequence
that led to their final treatment assignment (OM 40/AML
10/HCTZ 25 mg [given as OM 40/HCTZ 25 mg fixed-dose
combination plus AML 10 mg given separately], OM
40/AML 10 mg [fixed-dose combination], OM 40/HCTZ
25 mg [fixed-dose combination], or AML 10/HCTZ 25 mg
[given separately]). All participants received dual-combi-
nation treatment for 2 weeks, except for a subset of 36
study participants who had not been on antihypertensive
medications for at least 3 weeks and who received pla-
cebo for 2 weeks (in order to assess the study for non-
treatment-associated BP effects). All participants assigned
to dual-combination treatment remained on their assigned
treatment until week 4. All participants on placebo at week
2 were switched to 1 of the 3 dual-combination treatments
from week 2 to week 4. At week 4, participants were either
maintained on dual-combination treatment to week 12
or switched to triple-combination treatment with OM
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40/AML 10/HCTZ 25 mg until week 12. Study partici-
pants were instructed to take all study medication at the
same time (±2 h) each day and investigators and study
participants remained blinded as to which medication was
being administered at any given time [12].
BP was measured at all study visits during the double-
blind treatment period, including day 1 and weeks 2, 4, 6,
8, 10, and 12. BP was measured at all sites using an
automated BP monitor (OMRON HEM-705CP, Omron
Healthcare, Inc., Bannockburn, Illinois) that produced a
printout of each BP assessment with the use of a cuff of
appropriate size. Measurements were taken with the patient
in a seated position after a 5-min rest. Three BP mea-
surements were obtained at 1-min intervals during each
visit [12].
2.3 Efficacy Assessments
The primary efficacy variable was the least squares (LS)
mean change from baseline to week 12 in SeDBP in each
age subgroup. Secondary efficacy variables included the
LS mean change from baseline to week 12 in SeSBP,
proportion of study participants reaching SeBP goal (\140/
90 mmHg [\130/80 mmHg in study participants with
diabetes, chronic kidney disease, or chronic cardiovascular
disease]) at week 12, proportion of study participants
achieving SeBP target (\140/90 mmHg) at week 12
(subgroup post hoc analysis), and the mean change in SeBP
from baseline to week 12 in study participants with
severe hypertension (SeSBP C180 mmHg or SeDBP
C110 mmHg) at baseline (subgroup post hoc analysis).
2.4 Safety Assessments
Safety was assessed at all study visits. Safety assessments
included physical examinations (including vital signs),
12-lead electrocardiograms, clinical laboratory testing, and
adverse events.
2.5 Statistical Analysis
The primary efficacy analysis included all study partici-
pants who had baseline assessment of SeDBP, received at
least 1 dose of study medication, and had at least 1 post-
dose assessment of SeDBP (efficacy cohort). The primary
safety population for the assessment of adverse events was
defined as study participants who took at least 1 dose of
study medication at or beyond the week 4 visit (first-week
participants randomized to triple-combination treatment
actually received this treatment [safety cohort]).
The efficacy of triple- versus each dual-combination
treatment in reducing SeBP within age subgroups was
assessed using two-sided p-values derived from an analysis
of covariance (ANCOVA) model that had baseline BP as a
covariate and final randomized treatment, subgroup, and
final randomized treatment by subgroup interaction as fixed
effects. The LS mean difference and standard error (SE)
derived from the ANCOVA model were used to calculate
the baseline change in SeBP at week 12. The proportion of
study participants reaching BP goal and target by treatment
within age subgroups was summarized and analyzed using
the chi-square test. The efficacy of triple-combination
treatment versus each dual-combination treatment in
reaching BP goal and target with age subgroups was
assessed using Fisher’s exact test at a 0.05 significance
level. To account for potential missing data during the
double-blind treatment period, each of these analyses used
a last observation carried forward (LOCF) approach.
The TRINITY study was powered to assess treatment
efficacy in the overall study population. Sample size was
determined assuming 97 % power for each of the 3 pair-
wise comparisons of interest so that a desired overall power
of 90 % could be achieved. The study was not powered to
assess efficacy between age subgroups. In addition, there
was a small number of study participants in the C75 years
of age subgroup (79 [3.2 %]) who were included in the
C65 years of age subgroup. In the C75 years of age sub-
group, there were only 25, 19, 17, and 18 participants
receiving OM 40/AML 10 mg, OM 40/HCTZ 25 mg,
AML 10/HCTZ 25 mg, and OM 40/AML 10/HCTZ
25 mg, respectively. For these reasons, the evaluation of
the C75 years of age subgroup was for observational pur-




Of the 2492 study participants randomized in the TRINITY
study (total cohort), 2021 (81.1 %) were\65 years of age and
471 (18.9 %) were C65 years of age, including 79 (3.2 %)
who were C75 years of age. Mean ages in the C65 and
\65 years of age subgroups were 70.5 (minimum: 65, max-
imum: 92 years) and 51.5 (minimum: 20, maximum:
64 years), respectively. Both subgroups had a similar preva-
lence of male participants (C65 years of age: 51.2 %;
\65 years of age: 53.3 %). However, study participants
C65 years of age had a greater prevalence of diabetes than
study participants \65 years of age (21.4 vs. 14.2 %,
respectively), a lower mean body mass index (31.3 vs.
33.5 kg/m2), a longer mean duration of hypertension (14.4 vs.
8.9 years), a greater mean SeSBP (173.5 vs. 167.3 mmHg), a
lower mean SeDBP (96.6 vs. 102.0 mmHg), and a greater
prevalence of severe hypertension (30.6 vs. 24.1 %) at
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baseline. Mean SeBP at baseline was similar in the C75 and
C65 years of age subgroups (174.5/94.7 and 173.5/
96.6 mmHg, respectively) and the prevalence of severe
hypertension was 34.2 % in the C75 years of age subgroup
and 30.6 % in the C65 years of age subgroup.
Table 1 summarizes demographic and clinical charac-
teristics at baseline by randomized treatment assignment
for each age subgroup.
3.2 Efficacy
Regardless of age, all 4 treatments resulted in significant
reductions from baseline in SeDBP and SeSBP at week 12
(LOCF; Fig. 1). Triple-combination treatment with OM
40/AML 10/HCTZ 25 mg resulted in significantly greater
SeBP reductions than any of the dual-combination treat-
ments in both the \65 and C65 years of age subgroups.
The efficacy of all 4 treatments in the C75 years of age
subgroup appeared comparable to the efficacy in the
C65 years of age subgroup as a whole. Overall, the LS
mean reduction in SeBP at week 12 with triple-combina-
tion treatment was approximately 38/21 mmHg in study
participants \65 years of age (p \ 0.0001 vs. each dual-
combination treatment), approximately 39/24 mmHg in
study participants C65 years of age (p B 0.002 vs. each
dual-combination treatment), and approximately
40/26 mmHg in study participants C75 years of age. In
each age subgroup, the efficacy of triple- versus dual-
combination treatment was typically present within
2 weeks (week 6) of initiating OM 40/AML 10/HCTZ
25 mg (week 4), and was maintained throughout the
remainder of the double-blind treatment period (Fig. 2).
As a result, triple-combination treatment was signifi-
cantly more effective than the component dual-combination
treatments in enabling study participants \65 and
C65 years of age to reach BP goal (\140/90 or \130/
80 mmHg in study participants with diabetes, chronic kid-
ney disease, or chronic cardiovascular disease) at week 12
(LOCF), and numerically similar findings were seen in the
C75 years of age subgroup (Fig. 3). Overall, approximately
65, 63, and 56 % of study participants randomized to triple-
combination treatment in the \65, C65, and C75 years of
age subgroups, respectively, reached BP goal at week 12
(Fig. 3). Likewise, triple-combination treatment was more
effective than the component dual-combination treatments
in achieving the BP target of \140/90 mmHg at week 12
(LOCF) in all 3 age subgroups (Fig. 4; post hoc analysis).
The efficacy of triple- versus dual-combination treat-
ment appeared to be maintained across age subgroups in
the subset of study participants with severe hypertension
(SeSBP C180 mmHg or SeDBP C110 mmHg). In this
subset, mean SeBP at week 12 (LOCF) in study partici-
pants randomized to triple-combination treatment in the
\65, C65, and C75 years of age subgroups was reduced
approximately 47/24, 50/23, and 47/21 mmHg, respec-
tively, compared with mean reductions of 36–38/18–21,
38–41/16–18, and 36–43/17–22 mmHg in study partici-
pants randomized to dual-combination treatments in the
same age subgroups (Fig. 5; post hoc analysis).
An ad hoc analysis was performed to determine if there
was a trend toward BP reduction using age as a continuous
covariate. A linear regression analysis for change in BP
from baseline to the end of the 12-week treatment period
demonstrated statistical significance (p \ 0.05) for triple-
combination therapy for both SeDBP and SeSBP. The only
other combination therapy which demonstrated a similar
pharmacodynamic effect for BP reduction was the dual
combination of AML 10/HCTZ 25 mg.
3.3 Safety
Triple- and dual-combination treatments were safe and
well tolerated across age subgroups and no new safety
concerns were identified that were not known to occur with
the individual component therapies (Table 2). Overall,
1034 (55.6 %), 253 (57.1 %), and 36 (50.7 %) study par-
ticipants in the\65, C65, and C75 years of age subgroups,
respectively, had a treatment-emergent adverse event
(TEAE) and 474 (25.5 %), 111 (25.1 %), and 17 (23.9 %)
study participants in these same age subgroups had a drug-
related TEAE. Most of these adverse events were consid-
ered mild or moderate in severity across both treatment and
age subgroups. Serious adverse events occurred in 22
(1.2 %), 13 (2.9 %), and 1 (1.4 %) study participant(s) in
the \65, C65, and C75 years of age subgroups, respec-
tively, and 40 (2.2 %), 13 (2.9 %), and 3 (4.2 %) study
participants in these same age subgroups discontinued their
study medication due to an adverse event.
TEAEs occurring in C3 % of study participants on any
treatment regimen in the \65 or C65 years of age sub-
groups are listed in Table 2. The most common TEAEs
(C5 % in any treatment group) were dizziness (7.2 %),
headache (6.4 %), peripheral edema (5.5 %), and fatigue
(5.5 %) in the \65 years of age subgroup; peripheral
edema (7.9 %), headache (7.0 %), dizziness (6.3 %), and
fatigue (5.2 %) in the C65 years of age subgroup; and
peripheral edema (8.5 %), joint swelling (7.0 %), upper
respiratory tract infection (5.6 %), and dizziness (5.6 %) in
the C75 years of age subgroup. However, in the C75 years
of age subgroup, no more than 3 participants experienced 1
of these TEAEs on any treatment regimen. In particular,
the incidence of hypotension (\65 years of age: 0.4 %;
C65 years of age: 0.7 %), vertigo (\65 years of age:
0.3 %; C65 years of age: 0.5 %), and falls (\65 years of
age: 0.3 %; C65 years of age: 0.7 %) were low across age
subgroups for all treatment regimens. Orthostatic
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hypotension was experienced in 0.2 % of participants who
were \65 years of age and was not reported in any par-
ticipant C65 years of age in any treatment group.
There were no clinically relevant differences in the
incidence of TEAEs between study participants \65 and
C65 years receiving triple-combination treatment.
Although the number of participants in the C75 years of
age subgroup who were receiving triple-combination
treatment was small (n = 16), there did not appear to be
any clinically relevant differences in the incidence of TE-
AEs between this age subgroup (overall incidence: 56 %)
and the other age subgroups.
4 Discussion
This prespecified subgroup analysis of the TRINITY study
demonstrated the efficacy and safety of triple-combination
OM 40/AML 10/HCTZ 25 mg treatment in elderly par-
ticipants with hypertension. Compared with the component
dual-combination treatments, triple-combination treatment
with OM/AML/HCTZ resulted in greater mean reductions
in BP and enabled a larger proportion of study participants
to achieve BP goals in all 3 age subgroups. All treatments
were well tolerated. The largest BP reductions observed in
this evaluation occurred in the very elderly (C75 years of
age) in participants receiving OM 40/AML 10/HCTZ
25 mg (n = 18). This subgroup was a subset of the
C65 years of age subgroup, which may have contributed to
the demonstrated efficacy. The C75 years of age subgroup
also had the highest absolute rates of cardiovascular dis-
ease in patients receiving OM 40/AML 10/HCTZ 25 mg.
The potential impact of these observations is substantial
because epidemiologic data suggest that a reduction in SBP
of 20 mmHg or DBP of 10 mmHg has the potential to
reduce adverse events by as much as 50 % [6]. The
favorable benefits observed in outcome trials have resulted
in current guidance that hypertension should be treated
vigorously in all patients, regardless of age [2]. In general,
those with the best BP control also have the best outcomes.
Thus, the Seventh Report of the Joint National Committee
on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure (JNC 7) recommends a BP goal of
\140/90 mmHg (\130/80 mmHg in patients with diabetes
or chronic kidney disease), regardless of age [2].
Numerous clinical trials have established the benefits of
hypertension treatment in these patients [13–24]. In the
1980s, the European Working Party on High Blood Pres-
sure in the Elderly (EWPHE) demonstrated in a random-
ized, double-blind, placebo-controlled study that treating
hypertension in participants C60 years of age significantly
reduced cardiac (38 %, p = 0.036) and cardiovascular
(27 %, p = 0.037) mortality [13]. More recently, the
Hypertension in the Very Elderly Trial (HYVET) demon-
strated that treating hypertension in participants C80 years
of age to SBP values\150 mmHg reduced heart failure by
64 % (p \ 0.001), stroke mortality by 39 % (p = 0.046),
cardiovascular mortality by 23 % (p = 0.06), and all-cause
mortality by 21 % (p = 0.02) [20]. Consistent with these
findings, a meta-analysis of data from 15 trials found that
treating hypertension in participants C60 years of age
significantly reduced all-cause mortality (risk ratio [RR]:
0.90; 95 % confidence interval [CI]: 0.84–0.97), cardio-
vascular mortality (RR: 0.77; 95 % CI: 0.68–0.86),
Fig. 1 Least squares (LS) mean reductions in seated diastolic blood
pressure (SeDBP; primary efficacy variable) and seated systolic blood
pressure (SeSBP) at week 12 (last observation carried forward) by
treatment and age. Error bars depict standard error (SE) of BP
change. *p \ 0.0001 vs baseline; p \ 0.0001 vs each dual-
combination treatment within age subgroup; p = 0.002 vs OM
40/AML 10 mg treatment within age subgroup; §p \ 0.0001 vs OM
40/HCTZ 25 mg and AML 10/HCTZ 25 mg treatments within age
subgroup. AML = amlodipine besylate; HCTZ = hydrochlorothia-
zide; OM = olmesartan medoxomil
554 A. J. Lewin et al.
coronary heart disease mortality (RR: 0.77; 95 % CI:
0.65–0.90), and cerebrovascular mortality (RR: 0.66; 95 %
CI: 0.53–0.82) [21].
Combination therapy is an attractive approach [2].
Successfully applying advanced BP goals in elderly
patients remains challenging [1, 2]: only about 20 % of
these patients achieve the recommended BP targets [2]. In
hypertension, the etiology of BP elevation is usually mul-
tifactorial, making it unlikely that BP control can be
achieved by modulating a single mechanism [4, 25]. The
JNC 7 guidelines state that most patients with hypertension
require 2 or more antihypertensive medications to achieve
BP goal but overall, at least 75 % of patients with hyper-
tension will require at least 2 agents and at least 25 % need
at least 3 agents to achieve BP goal (these percentages
represent data from a controlled environment of a clinical
trial and findings cannot be extrapolated to the general
population) [2, 7, 25–29]. In the Study on Cognition and
Prognosis in the Elderly (SCOPE), 49 % of participants
randomized to active treatment were receiving at least 3
antihypertensive agents by study end [7]. Similarly, in the
Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pres-
sure Lowering Arm (ASCOT-BPLA), 78 % of participants
with hypertension and C3 other cardiovascular risk factors
were receiving at least 2 and 61 % at least 3 antihyper-
tensive agents by study end; addition of a third antihy-
pertensive agent resulted in approximately 30 % of
participants with previously uncontrolled hypertension
achieving BP goal (\140/90 mmHg [\130/80 mmHg in
participants with diabetes]) [30, 31]. Thus, the American
College of Cardiology Foundation (ACCF)/American
Heart Association (AHA) 2011 Expert Consensus Docu-
ment on Hypertension in the Elderly recommends adding a
third drug from another class if the antihypertensive
Fig. 2 Mean seated systolic
blood pressure (SeSBP; a) and
seated diastolic blood pressure
(SeDBP; b) from baseline to
week 12 by treatment and age.
Week 4 is the first week of
triple-combination treatment.
Prior to week 4, study
participants randomized to
triple-combination treatment
received 1 of 3 dual-
combination regimens.
AML = amlodipine besylate;
HCTZ = hydrochlorothiazide;
OM = olmesartan medoxomil
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response is inadequate compared to full doses of 2 drugs
from different classes [4].
BP control in the elderly is also complicated by adverse
events, such as hypotension, and drug interactions [4].
Elderly patients are also more likely to have end organ
damage that may influence drug selection and response to
therapy [2, 4]. In addition, pathophysiologic, lifestyle, and
treatment-related factors in these patients may adversely
affect compliance with any antihypertensive therapeutic
regimen [4].
In the present study, triple-combination treatment was
well tolerated in participants \65 and C65 years of age,
with a similar prevalence of TEAEs (57.7 and 61.0 %),
drug-related TEAEs (27.6 and 30.5 %), and study drug
discontinuations due to a TEAE (3.9 and 4.2 %). The
incidence of hypotension was similar across age groups
(\65 years of age: 0.4 %; C65 years of age: 0.7 %);
however, more participants C75 years of age (4.2 %) dis-
continued their study medication due to an adverse event
compared with participants \65 years of age (2.2 %) and
Fig. 3 Proportion of study
participants reaching blood
pressure (BP) goal (\140/
90 mmHg [\130/80 mmHg in
study participants with diabetes,
chronic kidney disease, or
chronic cardiovascular disease])
at week 12 (last observation
carried forward) by treatment
and age. *p \ 0.0001,
p B 0.0004 vs each
dual-combination treatment
within age subgroup.
AML = amlodipine besylate;
HCTZ = hydrochlorothiazide;
OM = olmesartan medoxomil
Fig. 4 Proportion of study participants achieving blood pressure
(BP) target (\140/90 mmHg) at week 12 (last observation carried
forward) by treatment and age (post hoc analysis). *p \ 0.0001,
p \ 0.005 vs each dual-combination treatment within age subgroup.
AML = amlodipine besylate; HCTZ = hydrochlorothiazide; OM =
olmesartan medoxomil
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C65 years of age (2.9 %). OM either as monotherapy or in
combination with HCTZ and/or AML is an effective and
safe treatment for hypertension in a broad range of patients,
including the elderly [32–36]. In one study, 52–67 % of
study participants C65 years of age receiving OM/HCTZ
combination therapy achieved the SeBP goal of \140/
90 mmHg, while in another study, 61 % of participants
C65 years of age receiving OM/AML combination ther-
apy, with or without HCTZ, achieved the SeBP goal of
\140/90 mmHg (\130/80 mmHg in participants with
diabetes) [32, 34]. In patients with diabetes, chronic kidney
disease, or chronic cardiovascular disease, short-term
(12 weeks) and long-term treatment with OM 40/AML
10/HCTZ 25 mg was well tolerated, lowered BP more
effectively, and enabled more participants to reach BP goal
than the corresponding dual-combination therapies [37].
Furthermore, in another multinational, phase 3 study,
adding HCTZ to a range of OM/AML dose combinations
was well tolerated and improved BP control by signifi-
cantly lowering BP in patients with moderate-to-severe
hypertension [38].
A critical factor in achieving benefit is adherence to
therapy, which has been shown to correlate inversely with
the number of pills in a therapeutic regimen [8, 9, 39].
Nonadherence is a major contributing factor to inadequate
BP control [40–42] and can be particularly problematic in
elderly individuals taking polypharmacotherapy (often with
6 or more medications) for multiple comorbidities [4]. The
ACC/AHA 2011 Expert Consensus states that potential
benefits of single-pill combination therapy include
increased efficacy, reduced adverse events, and additive
target organ protection [4]. Furthermore, by decreasing the
number of copayments required, this therapy could reduce
out-of-pocket costs, an important consideration in the
elderly due to lower incomes [4, 43]. Thus, single-pill
combination therapy provides a convenient and effective
option for many patients that may increase adherence and
persistence [44–49].
Certain limitations exist in this study. While the evalu-
ation of the elderly (C75 years of age and C65 years of
age) and non-elderly subgroups (\65 years of age) was
pre-defined, statistical analyses between these subgroups
was not completed because of the unequal participant
numbers in the subgroups. Achieved SeBP reductions were
comparable with treatment cohorts and the age subgroups
and did not warrant further analyses between subgroups.
Participants with various illnesses, including active heart
disease and poorly controlled diabetes (i.e., HbA1c [9 %),
were excluded from participation; therefore, caution must
be exercised regarding generalizability of these data to the
overall population. In addition, the TRINITY study eval-
uated only a single dose for each agent used and therefore
does not provide information on the efficacy or safety of
these regimens using different dosing schemes. Also, in
clinical practice, patients are likely to be titrated from no
drugs to 1 drug, 2 drugs, and then a regimen with 3 drugs.
While the TRINITY 12-week study is not designed in this
way, it is reasonable to assume that if patients were titrated
in the study as they are in clinical practice, the total BP
reduction would be similar.
5 Conclusions
This prespecified subgroup analysis of the TRINITY study
demonstrated that OM 40/AML 10/HCTZ 25 mg triple-
combination treatment was both safe and effective in study
participants with hypertension, regardless of age. Triple-
combination treatment resulted in greater reductions in
SeSBP and SeDBP and, as a result, was more effective in
enabling study participants to reach BP goal compared with
the component dual-combination treatments in all age
Fig. 5 Mean reductions in
blood pressure (BP) at week 12
(last observation carried
forward) by treatment and age
in study participants with severe
hypertension at baseline (post
hoc analysis). Severe
hypertension was defined as
seated systolic BP (SeSBP)
C180 mmHg or seated diastolic
BP (SeDBP) C110 mmHg.
AML = amlodipine besylate;
HCTZ = hydrochlorothiazide;
OM = olmesartan medoxomil;
SD = standard deviation
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subgroups. Triple-combination treatment was well toler-
ated, with low prevalences of hypotension and few dis-
continuations due to drug-related TEAEs in both the \65
and C65 years of age subgroups. Triple-combination
treatment with OM 40/AML 10/HCTZ 25 mg may provide
a safe and effective treatment option for elderly patients
whose BP is not adequately controlled with dual-combi-
nation treatment. Other combinations of similar classes of
medications may be efficacious at reducing BP, but will
need to be evaluated.
Table 2 Study participants with TEAEs by treatment and agea

















ALL TEAEs 250 (51.8) 58 (51.3) 254 (55.6) 65 (52.8) 267 (57.7) 58 (65.2) 263 (57.7) 72 (61.0)
Drug-related TEAEsc 116 (24.0) 22 (19.5) 97 (21.2) 24 (19.5) 135 (29.2) 29 (32.6) 126 (27.6) 36 (30.5)
Discontinuations
TEAEs 5 (1.0) 1 (0.9) 9 (2.0) 3 (2.4) 7 (1.5) 4 (4.5) 18 (3.9) 5 (4.2)
Drug-related TEAEs 3 (0.6) 1 (0.9) 4 (0.9) 1 (0.8) 3 (0.6) 2 (2.2) 16 (3.5) 2 (1.7)
TEAEs (C3 % in any treatment group)
Dizziness 24 (5.0) 5 (4.4) 47 (10.3) 11 (8.9) 14 (3.0) 3 (3.4) 48 (10.5) 9 (7.6)
Headache 34 (7.0) 8 (7.1) 30 (6.6) 8 (6.5) 27 (5.8) 6 (6.7) 28 (6.1) 9 (7.6)
Upper respiratory tract
infection
19 (3.9) 7 (6.2) 16 (3.5) 2 (1.6) 12 (2.6) 2 (2.2) 13 (2.9) 3 (2.5)
Edema peripheral 34 (7.0) 8 (7.1) 4 (0.9) 2 (1.6) 36 (7.8) 10 (11.2) 29 (6.4) 15 (12.7)
Fatigue 30 (6.2) 4 (3.5) 25 (5.5) 6 (4.9) 29 (6.3) 7 (7.9) 18 (3.9) 6 (5.1)
Nausea 9 (1.9) 3 (2.7) 18 (3.9) 4 (3.3) 11 (2.4) 1 (1.1) 14 (3.1) 3 (2.5)
Hypokalemia 1 (0.2) 1 (0.9) 3 (0.7) 0 23 (5.0) 2 (2.2) 3 (0.7) 1 (0.8)
Urinary tract infection 7 (1.4) 1 (0.9) 5 (1.1) 1 (0.8) 6 (1.3) 1 (1.1) 7 (1.5) 7 (5.9)
Arthralgia 8 (1.7) 4 (3.5) 9 (2.0) 2 (1.6) 9 (1.9) 3 (3.4) 8 (1.8) 0
Joint swelling 11 (2.3) 6 (5.3) 1 (0.2) 1 (0.8) 12 (2.6) 4 (4.5) 3 (0.7) 9 (7.6)
Constipation 4 (0.8) 2 (1.8) 3 (0.7) 3 (2.4) 12 (2.6) 0 5 (1.1) 5 (4.2)
Diarrhea 9 (1.9) 5 (4.4) 10 (2.2) 2 (1.6) 8 (1.7) 1 (1.1) 10 (2.2) 5 (4.2)
Nasopharyngitis 10 (2.1) 1 (0.9) 15 (3.3) 5 (4.1) 13 (2.8) 3 (3.4) 17 (3.7) 3 (2.5)
Muscle spasms 8 (1.7) 4 (3.5) 11 (2.4) 3 (2.4) 11 (2.4) 2 (2.2) 17 (3.7) 1 (0.8)
Paraesthesia 8 (1.7) 1 (0.9) 8 (1.8) 0 6 (1.3) 3 (3.4) 4 (0.9) 0
Dry mouth 4 (0.8) 1 (0.9) 6 (1.3) 2 (1.6) 7 (1.5) 3 (3.4) 3 (0.7) 2 (1.7)
Blood glucose increased 1 (0.2) 2 (1.8) 0 1 (0.8) 6 (1.3) 3 (3.4) 1 (0.2) 0
Blood potassium
decreased
1 (0.2) 0 3 (0.7) 0 10 (2.2) 4 (4.5) 5 (1.1) 0
Rash 4 (0.8) 4 (3.5) 4 (0.9) 1 (0.8) 6 (1.3) 2 (2.2) 3 (0.7) 2 (1.7)
Other TEAEs
Cough 7 (1.4) 0 12 (2.6) 3 (2.4) 9 (1.9) 2 (2.2) 8 (1.8) 3 (2.5)
Hypotension 0 0 2 (0.4) 1 (0.8) 0 0 6 (1.3) 2 (1.7)
Orthostatic hypotension 0 0 1 (0.2) 0 0 0 2 (0.4) 0
Vertigo 2 (0.4) 0 1 (0.2) 0 0 1 (1.1) 2 (0.4) 1 (0.8)
Fall 1 (0.2) 0 2 (0.4) 1 (0.8) 2 (0.4) 1 (1.1) 1 (0.2) 1 (0.8)
a Due to the disproportionate sizes of the age groups and because the C75 years of age group is included in the C65 years of age group, only
TEAEs C3 % for the \65 years of age and C65 years of age groups are shown
b TEAEs were adverse events that emerged during treatment, having been absent pre-treatment or worsened relative to the pre-treatment state.
TEAEs are defined as having a start date on or after the first dose of double-blind medication
c Drug-related was defined as definitely, probably, or possibly related to randomized study medication
AML = amlodipine besylate; HCTZ = hydrochlorothiazide; NR = not reported; OM = olmesartan medoxomil; TEAE = treatment-emergent
adverse event
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